Fonte: Cancer Research. Unidade: FM
Assuntos: VACINAS VIRAIS, IMUNIZAÇÃO, ONCOGENES, NEOPLASIAS DO COLO UTERINO, ANTICORPOS, BIOMARCADORES, HPV (IMUNOLOGIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LU, Beibei et al. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research, v. 72, n. 3, p. 676-685, 2012Tradução . . Disponível em: https://doi.org/10.1158/0008-5472.CAN-11-0751. Acesso em: 05 jul. 2024.APA
Lu, B., Viscidi, R. P., Wu, Y., Lee, J. -H., Nyitray, A. G., Villa, L. L., et al. (2012). Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men. Cancer Research, 72( 3), 676-685. doi:10.1158/0008-5472.CAN-11-0751NLM
Lu B, Viscidi RP, Wu Y, Lee J-H, Nyitray AG, Villa LL, Lazcano-Ponce E, Silva RJC da, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men [Internet]. Cancer Research. 2012 ; 72( 3): 676-685.[citado 2024 jul. 05 ] Available from: https://doi.org/10.1158/0008-5472.CAN-11-0751Vancouver
Lu B, Viscidi RP, Wu Y, Lee J-H, Nyitray AG, Villa LL, Lazcano-Ponce E, Silva RJC da, Baggio ML, Quiterio M, Salmeron J, Smith DC, Abrahamsen ME, Papenfuss MR, Stockwell HG, Giuliano AR. Prevalent Serum Antibody Is Not a Marker of Immune Protection against Acquisition of Oncogenic HPV16 in Men [Internet]. Cancer Research. 2012 ; 72( 3): 676-685.[citado 2024 jul. 05 ] Available from: https://doi.org/10.1158/0008-5472.CAN-11-0751
